BPLPHARMA Bharat Parenterals Q2 FY27 results (Jul–Sep 2026) and concall
Bharat Parenterals delivered a strong turnaround in Q2 FY27, posting consolidated revenue of ₹136.3 crores and EBITDA of ₹23.6 crores (17.3% margin) as the multi-year investment in its subsidiaries began to yield results. Innoxel Life Sciences emerged as the key growth engine, accounting for over 60% of group EBITDA and completing its first commercial US export on October 20, 2026. The standalone business demonstrated steady volume execution but faced input cost headwinds that depressed quarterly gross margins to 35%. With ₹139 crores raised via preferential allotment and robust H1 cash flow f
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 88.4%, net profit up 98.5% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 67 | 80 | 94 | 42 | 41 −39% | 57 −30% | 56 −41% | 79 +88% |
| EBITDA | 8 | 5 | 15 | 2 | 3 −58% | 0 −99% | 7 −55% | 7 +201% |
| Net profit | 7 | 2 | 10 | 3 | 2 −70% | 1 −39% | 4 −63% | 5 +99% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
